← back to search

Mark A. Dawson

The University of Melbourne · AU
Area of research
Immunology · Oncology
Research interest
Research interests include interferon and immune responses, Cytokine Signaling Pathways and Interactions, Protein Degradation and Inhibitors, and Cancer-related molecular mechanisms research.
h-index
55
citations
19,095
works
380
NIH funding
primary concept
Medicine
email

Recent publications

Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia
Cancer Discovery 2025cited by 13position: lastdoi
The Epigenetic Hallmarks of Cancer
Cancer Discovery 2024cited by 121position: middledoi
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation
Blood 2024cited by 14position: middledoi
HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults
Nature Medicine 2021cited by 103position: middledoi
Targeting the epigenetic regulation of antitumour immunity
Nature Reviews Drug Discovery 2020cited by 617position: middledoi
Non-genetic mechanisms of therapeutic resistance in cancer
Nature reviews. Cancer 2020cited by 600position: lastdoi
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity
Nature Cancer 2020cited by 110position: middledoi
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
Cancer Cell 2019cited by 630position: lastdoi
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
Nature Communications 2019cited by 178position: lastdoi
Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
Cell stem cell 2019cited by 91position: middledoi
5-Formylcytosine organizes nucleosomes and forms Schiff base interactions with histones in mouse embryonic stem cells
Nature Chemistry 2018cited by 100position: middledoi
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Nature 2017cited by 941position: lastdoi
Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study
Clinical Infectious Diseases 2014cited by 406position: middledoi
Cancer Epigenetics: From Mechanism to Therapy
Cell 2012cited by 3,184position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Paul A. Beavis · Peter MacCallum Cancer Centre2 papers (2017–2020)Sarah‐Jane Dawson · AGRF Ltd2 papers (2017–2020)Eun‐Ang Raiber · Cancer Research UK Cambridge Center1 papers (2018–2018)Tony Kouzarides · University of Cambridge1 papers (2012–2012)Sabine Stolzenburg · The University of Western Australia1 papers (2017–2017)Paul J. Lehner · University of Cambridge1 papers (2017–2017) · 1 papers (2018–2018)Charles C. Bell · The University of Queensland1 papers (2017–2017)Christina E. Sparbier · Peter MacCallum Cancer Centre1 papers (2017–2017)Peter A. Jones · Van Andel Institute1 papers (2024–2024)Zhe Li · Indiana University School of Medicine1 papers (2018–2018)Zheng Liu · Guilin Medical University1 papers (2018–2018)Sergio Martínez Cuesta · Cancer Research UK Cambridge Center1 papers (2018–2018)Ilia Voskoboinik · The University of Melbourne1 papers (2017–2017)Marian L. Burr · Australian National University1 papers (2017–2017)Yih-Chih Chan · The University of Melbourne1 papers (2017–2017)Jean‐Christophe Marine · Cancer Research UK1 papers (2020–2020)Manel Esteller · Hospital de Sant Pau1 papers (2024–2024) · 1 papers (2018–2018)Michael C. Bassik · Stanford University1 papers (2017–2017)